- Astellas Pharma‘s first-quarter operating income of 94.65 billion yen was a significant 87% increase from the previous year and exceeded the estimated 80.54 billion yen.
- The company’s net income reached 68.42 billion yen, showing an impressive 82% rise year-over-year and surpassing the forecast of 32.38 billion yen.
- Net sales were recorded at 505.79 billion yen, a 6.9% increase from the same quarter last year, outperforming the projected 465.49 billion yen.
- Research and development expenses were reduced by 17% to 71.70 billion yen, lower than the anticipated 85.76 billion yen.
- For the year 2026, Astellas Pharma maintains its operating income forecast at 160.00 billion yen.
- The company continues to forecast its net income at 130.00 billion yen, slightly below the estimate of 139.96 billion yen.
- Astellas Pharma‘s net sales prediction remains at 1.93 trillion yen, slightly under the estimate of 1.95 trillion yen.
- The dividend forecast stands firm at 78.00 yen, marginally below the estimate of 78.31 yen.
- From analysts: 6 recommend buying, 9 suggest holding, and 1 advises selling Astellas Pharma‘s shares.
Astellas Pharma on Smartkarma
Analyst coverage on Astellas Pharma by independent research network Smartkarma reveals insightful perspectives on the company’s performance. Tina Banerjee, in one report titled “Astellas Pharma (4503 JP): Izervay on Strong Footing, Strategic Brands Key for Future,” highlights the remarkable 25% growth in Q1FY26 sales of Izervay in the U.S. and the significant improvement in revenue from strategic brands in FY25. The report also mentions Astellas’ collaboration with Evopoint Biosciences to enhance its pipeline, showcasing positive developments for the company.
Another report by Tina Banerjee, titled “Astellas Pharma (4503 JP): Strong FY25 Result; Cost Optimization to Boost FY26 Profit on Flat Sales,” discusses Astellas Pharma‘s impressive FY25 performance surpassing expectations. The analysis projects a 1% revenue growth in FY26 with a focus on cost optimization to drive profits. Key insights include expected growth in strategic brands and core operating profits, despite a slight revenue decline expected from Xtandi.
A look at Astellas Pharma Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 5 | |
| Growth | 2 | |
| Resilience | 2 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on Smartkarma Smart Scores, Astellas Pharma Inc. shows a promising long-term outlook. The company receives a strong score of 5 in the Dividend category, indicating a robust dividend payment track record. Furthermore, Astellas Pharma scores moderately in the Value and Momentum categories with scores of 3 each, suggesting a balanced approach to valuation and market momentum. However, the Growth and Resilience categories are rated lower at 2 each, indicating room for improvement in terms of growth potential and resilience to market fluctuations.
Astellas Pharma Inc., a pharmaceutical company dedicated to various therapeutic fields, employs over 17,000 individuals globally. Specializing in Urology, Immunology, Oncology, Neuroscience, and more, Astellas conducts research, development, manufacturing, and marketing of prescription drugs through its subsidiaries across the US, Europe, and Asia. The company’s strong focus on dividend distribution, along with its diverse portfolio, positions it well for sustained success in the pharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
